Paladin Labs is focused on in-licensing pharmaceutical products for the Canadian and world markets.
Paladin Labs interim president and CEO Mark Beaudet said the acquisition of Labopharm will add established international revenue streams besides providing the opportunity to build upon their existing operational capabilities.
"Moreover, Labopharm’s worldwide partnerships provide us with an exciting opportunity to continue cultivating important relationships internationally," Beaudet added.